Genmab — November 2017
-
You are far too optimistic. It will not happen.
-
Well in Q4-2016 everybody also said 1400 within 6 month was too optimistic and we hit 1488 in april 2017 so I thinl its realsisic with 1700 in April 2018 - also seen from the point of view that C20, DAX etc. increased +15% in 2017 and Genmab now underperforming compared to C20
-
The Dutch National Health Care Institute advising NOT to add daratumumab to the base Insurance package, unless price negotiations improve cost-effectiveness https://www.zorginstituutnederland.nl/publicaties/adviezen/2017/11/29/pakketadvies-daratumumab-darzalex-bij-multipel-myeloom
-
-
Are the Dutch the European mainland Scottish? Why not give it for free?

-
Det hele drejer sig vel bare om,at større investorer mener at de kan finde bedre afkastmuligheder på kort- eller mellemlang sigt end de kan i Genmab. Den slags er jo helt almindeligt forekommende i de fleste udviklingsselskabers historik.
Hello! It looks like you're interested in this conversation, but you don't have an account yet.
Getting fed up of having to scroll through the same posts each visit? When you register for an account, you'll always come back to exactly where you were before, and choose to be notified of new replies (either via email, or push notification). You'll also be able to save bookmarks and upvote posts to show your appreciation to other community members.
With your input, this post could be even better 💗
Tilmeld Log ind